嘉应制药
(002198)
| 流通市值：40.30亿 | | | 总市值：40.30亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 216,891,217.73 | 171,519,328.83 | 118,503,980.73 | 133,506,919.66 |
| 应收票据及应收账款 | 102,500,776.24 | 111,021,909.42 | 115,573,416.84 | 125,444,002.11 |
| 其中：应收票据 | 9,023,906.58 | 11,997,001.69 | 21,916,669.03 | 27,859,210.37 |
| 应收账款 | 93,476,869.66 | 99,024,907.73 | 93,656,747.81 | 97,584,791.74 |
| 应收款项融资 | 4,106,604 | 8,561,645.71 | 19,822,374.56 | 28,603,644.56 |
| 预付款项 | 24,961,016.51 | 2,296,508.27 | 14,810,649.41 | 4,372,714.79 |
| 其他应收款合计 | 2,518,475.51 | 6,647,481.72 | 3,718,683.49 | 2,003,147.59 |
| 存货 | 87,158,970.46 | 97,431,990 | 89,944,314.51 | 84,600,069.49 |
| 其他流动资产 | 340,934.54 | 1,611,828.51 | 492,243.33 | 1,113,247.86 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 518,605,435.65 | 539,253,639.97 | 583,240,490.87 | 580,173,699.06 |
| 非流动资产: | | | | |
| 长期股权投资 | 24,295,644.89 | 25,313,532.43 | 26,129,635.68 | 27,093,910.01 |
| 固定资产 | 179,475,578.29 | 181,059,003.69 | 184,098,554.11 | 188,748,094.53 |
| 在建工程 | 16,984,641.27 | 6,705,524.12 | 2,010,512.06 | 1,660,769.81 |
| 无形资产 | 46,298,734.32 | 46,549,605.15 | 46,878,887.4 | 47,208,169.65 |
| 长期待摊费用 | 469,402.7 | 190,773.8 | - | - |
| 递延所得税资产 | 2,443,200.68 | 2,553,332.41 | 2,166,191.35 | 2,185,270.15 |
| 其他非流动资产 | 7,440,371.5 | 14,419,832 | 430,200 | 493,200 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 277,407,573.65 | 276,791,603.6 | 261,713,980.6 | 267,389,414.15 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 796,013,009.3 | 816,045,243.57 | 844,954,471.47 | 847,563,113.21 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 2,327,087.37 | 13,906,939.33 | 12,931,493.69 | 9,156,200.35 |
| 应付账款 | 2,327,087.37 | 13,906,939.33 | 12,931,493.69 | 9,156,200.35 |
| 预收款项 | - | - | 37,431.17 | 1,046,712.81 |
| 合同负债 | 646,107.03 | 2,477,184.87 | 6,102,247.79 | 2,210,538.73 |
| 应付职工薪酬 | 3,547,493.07 | 3,216,146.3 | 2,623,835.52 | 6,041,390.76 |
| 应交税费 | 4,968,593.88 | 3,412,524.71 | 3,996,050.55 | 7,454,363.2 |
| 其他应付款合计 | 8,838,319.37 | 12,268,383.25 | 9,461,614.8 | 18,781,204.22 |
| 其他流动负债 | 79,382.23 | 2,365,520.52 | 6,450,092.8 | 4,648,478.91 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 20,406,982.95 | 37,646,698.98 | 41,602,766.32 | 49,338,888.98 |
| 非流动负债: | | | | |
| 递延收益 | 319,033.06 | 350,471.23 | 381,909.4 | 413,347.57 |
| 递延所得税负债 | 34,804,491.79 | 34,771,177.89 | 34,802,959.96 | 34,826,228.71 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 35,123,524.85 | 35,121,649.12 | 35,184,869.36 | 35,239,576.28 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 55,530,507.8 | 72,768,348.1 | 76,787,635.68 | 84,578,465.26 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 507,509,848 | 507,509,848 | 507,509,848 | 507,509,848 |
| 资本公积 | 123,652,931.39 | 123,652,931.39 | 123,652,931.39 | 123,652,931.39 |
| 盈余公积 | 27,223,004.6 | 27,223,004.6 | 27,223,004.6 | 27,223,004.6 |
| 未分配利润 | 82,096,717.51 | 84,891,111.48 | 109,781,051.8 | 104,598,863.96 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 740,482,501.5 | 743,276,895.47 | 768,166,835.79 | 762,984,647.95 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 740,482,501.5 | 743,276,895.47 | 768,166,835.79 | 762,984,647.95 |
| 负债和股东权益合计 | 796,013,009.3 | 816,045,243.57 | 844,954,471.47 | 847,563,113.21 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |